CH0329023102 - ACIU - A2AR5F (XNAS)
AC IMMUNE SA Aktie
3,71 USD
Aktuelle Kurse von AC IMMUNE SA
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
ACIU
|
USD
|
19.09.2024 21:59
|
3,71 USD
| 3,64 USD | 1,87 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
1,87 % | 21,89 % | 9,69 % | -9,34 % | 5,94 % | 23,19 % | -28,69 % |
Firmenprofil zu AC IMMUNE SA Aktie
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Investierte Fonds
Folgende Fonds haben in AC IMMUNE SA investiert:
Fonds | Vol. in Mio 17,87 | Anteil (%) 0,04 % |
Unternehmensdaten zur AC IMMUNE SA Aktie
Name AC IMMUNE SA
Firma AC Immune SA
Symbol ACIU
Website https://www.acimmune.com
Heimatbörse
NASDAQ
WKN A2AR5F
ISIN CH0329023102
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Andrea Pfeifer Ph.D.
Marktkapitalisierung 298 Mio
Land Schweiz
Währung USD
Mitarbeiter 0,1 T
Adresse Building B, 1015 Lausanne
IPO Datum 2016-09-23
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | IMR.F |
NASDAQ | ACIU |
Weitere Aktien
Investoren die AC IMMUNE SA halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024